AlbaCore Capital Brings Aboard Diarmuid Curran to Enhance European CLO Capabilities
LONDON, June 10, 2025--(BUSINESS WIRE)--European credit specialist, AlbaCore Capital Group ("AlbaCore"), has announced the appointment of Diarmuid Curran as Managing Director and Portfolio Manager.
Diarmuid will focus on AlbaCore's leading European CLO platform – both new issuance and existing CLO fund management, reporting to Deborah Cohen Malka, Partner and Portfolio Manager, who leads the CLO business.
"I'm pleased to welcome Diarmuid to the team at AlbaCore," said Deborah Cohen Malka. "His background and experience will strengthen our capabilities as we continue to take advantage of the pipeline of opportunities in Europe on behalf of our investor base."
Diarmuid joins AlbaCore from Napier Park Global Capital, where he served as a Portfolio Manager. In that capacity, he was responsible for managing a portfolio of European loans and High Yield bonds held in CLOs as well as credit selection and underwriting as a member of the Investment Committee.
"I've been impressed from afar by AlbaCore's reputation in the European market," said Diarmuid Curran. "I look forward to working with Deborah and the team to build upon their well-established European CLO business."
In March of this year, AlbaCore successfully priced AlbaCore Euro CLO VII - it's 7th CLO – bringing the total value of CLO platform assets under management to c. €2.9 billion.
The CLO platform incorporates negative ESG screening criteria in combination with AlbaCore's fundamental research and risk focused ESG considerations, including restrictions on the industries in which the CLO can invest.
About AlbaCore Capital Group
AlbaCore Capital Group is one of Europe's leading alternative credit specialists, investing in private capital solutions, direct lending, opportunistic and dislocated credit, CLOs, and structured products. Founded in 2016, AlbaCore is part of the First Sentier Investors Group. AlbaCore's investment philosophy is focused on capital preservation and generating attractive risk adjusted returns through the cycle for its investors. AlbaCore manages US $10.0 billion in AuM3 as of 31 March 2025 on behalf of global pension funds, sovereign wealth funds, endowments, insurance companies, family offices and high net worths around the world.
For more information, visit www.AlbaCoreCapitalGroup.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610829230/en/
Contacts
Media Contacts:
Lansons (London) Rakin Sayed +447581036067 rakins@lansons.com
Lansons (New York) James Schiavone 917-238-9614 jamess@lansons.com
Se produjo un error al recuperar la información
Inicia sesión para acceder a tu portafolio
Se produjo un error al recuperar la información
Se produjo un error al recuperar la información
Se produjo un error al recuperar la información
Se produjo un error al recuperar la información
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
27 minutes ago
- Washington Post
Rights group says global brands are at risk of links to forced labor in China's minerals industry
LONDON — Several global brands are among dozens of companies at risk of using forced labor through their Chinese supply chains because they use critical minerals or buy minerals-based products sourced from China's far-western Xinjiang region, an international rights group said Wednesday. The report by the Netherlands-based Global Rights Compliance says companies including Avon, Walmart, Nescafe, Coca-Cola and paint supplier Sherwin-Williams may be linked to titanium sourced from Xinjiang, where rights groups allege the Chinese government runs coercive labor practices targeting predominantly Muslim Uyghurs and other Turkic minorities.
Yahoo
an hour ago
- Yahoo
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
The latest trading session saw CRISPR Therapeutics AG (CRSP) ending at $42.94, denoting a +2.02% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of 0.55%. At the same time, the Dow added 0.25%, and the tech-heavy Nasdaq gained 0.63%. Shares of the company have appreciated by 11.97% over the course of the past month, outperforming the Medical sector's gain of 3.49% and the S&P 500's gain of 6.29%. Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.54 per share, which would represent a year-over-year decline of 3.36%. At the same time, our most recent consensus estimate is projecting a revenue of $5.89 million, reflecting a 1032.88% rise from the equivalent quarter last year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$5.54 per share and revenue of $39.95 million, indicating changes of -27.65% and +7.06%, respectively, compared to the previous year. It's also important for investors to be aware of any recent modifications to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 1.68% fall in the Zacks Consensus EPS estimate. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 76, placing it within the top 31% of over 250 industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Geek Vibes Nation
an hour ago
- Geek Vibes Nation
How ChatGPT Bots Handle Client DMs While I Sleep – And Land Me New Deals
A good fit Ready to start Needing more info' This prompt works with DM automation tools that support branching logic. I collect info while I sleep – and wake up knowing which leads are warm. Claude Prompt #6 – Turn Chat Transcripts Into CRM Notes Prompt: 'Summarize this DM chat into 3 bullet points for my CRM: Who they are What they need How to follow up' This is huge when you're juggling 20 conversations. Claude acts like a personal assistant that cleans up your notes, flags key info, and saves it to Notion, Airtable, or whatever you use. AI DM Bot Comparison Use Case Best Model Why It Works Warm intro DM ChatGPT Fast, friendly, low-friction copy Deep context follow-up Claude Reads nuance and builds trust FAQ automation ChatGPT Clear, reusable, scalable replies Lead qualification Claude Detects readiness, helps filter CRM note generation Claude Great for summarizing long convos The Real Win – Focus on Closing, Not Replying Since I implemented this ChatGPT + Claude + Chatronix setup, I spend less time chasing leads and more time closing deals. I don't lose prospects because I replied too late. I don't drop the ball on follow-ups. And I don't miss qualified leads buried in my DMs. It's not about automating relationships – it's about automating friction so real connection can happen. Want your DMs to work while you rest? ✅ Visit Chatronix and set up your dream AI sales assistant – without hiring anyone. Emily Henry writes for UKWritings Reviews and Write My Research Paper . She writes articles on many subjects including writing great resumes. Emily is also an editor at State Of Writing .
